Overview of Pyralgivet

Property	Description
Active ingredient	Metamizole Sodium (Dipyrone)
Form	Tablets, Oral Drops/Solution, Solution for Injection
Pharmacological class	Non-opioid Analgesic, Antipyretic, Spasmolytic Agent
Common use	Relief of pain and fever
Origin	Synthetic pyrazolone derivative

Pyralgivet: Defining the Non-Opioid Analgesic Class

Pyralgivet is a specific pharmaceutical preparation containing the active ingredient Metamizole Sodium, a potent compound recognized for its role in the symptomatic management of acute discomfort and fever. It is formally classified as a non-opioid analgesic, antipyretic, and spasmolytic agent. Unlike conventional Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metamizole is a synthetic substance belonging to the pyrazolone derivative chemical group. This distinction means Pyralgivet operates through different biological pathways than common medications like ibuprofen. Metamizole functions as a primary pain reliever in various acute settings. This signifies the medicine provides relief for strong, sudden pain.

Composition and Available Pharmaceutical Forms

The therapeutic action of Pyralgivet is delivered through a single active component, Metamizole Sodium, making it a monopreparation. This substance acts as a pro-drug, rapidly metabolizing into the active compound 4-Methylaminoantipyrine (4-MAA) upon administration. Pyralgivet is offered in multiple dosage forms, which include tablets and oral drops/solution for oral use, as well as a solution for injection for administration via intravenous or intramuscular routes. In its injectable form, the medicine is utilized for acute clinical care. This confirms the drug’s role in acute clinical care.

General Purpose and Triple Therapeutic Benefit

The core general purpose of Pyralgivet is to provide symptomatic intervention for significant acute discomfort, particularly when associated with elevated body temperature. Its pharmacological profile includes three established actions: strong pain suppression (analgesia), the reduction of high body temperature (antipyresis), and the relief of painful muscle tension (spasmolysis). This comprehensive triple-action effect allows the medicine to address pain, fever, and muscle contractions simultaneously, making it suitable for situations such as relieving the severe cramping associated with renal or biliary colic.

Regulatory References

WHO Essential Medicines Lists

What side effects are possible with Pyralgivet?

Possible Side Effects and Safety Information

Pyralgivet, which contains the active substance metamizole (also known as dipyrone), is generally considered relatively safe when used as directed in veterinary medicine. However, like all medications, it can be associated with side effects and requires adherence to specific safety precautions.

Potential Adverse Reactions

The most significant and controversial potential adverse effect, primarily studied in humans but warranting caution in all species, is agranulocytosis (a severe reduction in white blood cells). While this is considered very rare, it is potentially serious. Other hypersensitivity reactions, including shock and anaphylaxis, are also rare but possible, particularly following rapid intravenous administration.

Less frequent adverse reactions observed across target species (horses, cattle, pigs, and dogs) may include:

Gastrointestinal signs, such as ulceration of the digestive tract.
Effects related to the cardiovascular system, such as hypotension (low blood pressure) or mild tachycardia (increased heart rate) in horses.
Local irritation if administered subcutaneously (under the skin).

Contraindications and Safety Warnings

Pyralgivet is contraindicated and should not be used in animals with pre-existing conditions such as:

Haematopoietic disorders (blood-forming system problems).
Gastrointestinal ulceration.
Severe hepatic (liver) or renal (kidney) failure.
Hypersensitivity to metamizole or other pyrazolone derivatives.

Special Precautions: Intravenous administration must be performed slowly to minimize the risk of anaphylactic shock. Pyralgivet is not for use in cats due to the presence of benzyl alcohol in the formulation. Caution is advised when administering simultaneously with other drugs, particularly those that may affect the kidneys or central nervous system.

Overdose and Emergency Response

Pyralgivet Overdose and When to Seek Help

Information regarding overdose with Pyralgivet is derived strictly from official government-authorized regulatory documents, detailing documented manifestations and required emergency actions.

Documented Overdose Manifestations

Official labeling describes that Pyralgivet overdose may lead to acute toxicity involving the Central Nervous System, the Cardiovascular System, and the Respiratory System. Documented presentations include pronounced somnolence, acute confusion, and severe gastrointestinal distress such as intractable vomiting. In severe cases, the regulatory profile lists potentially life-threatening outcomes, including profound respiratory depression and severe cardiac rhythm disturbances (dysrhythmias) that may result in coma.

Required Emergency Actions

Official regulatory texts specify that urgent medical attention must be sought immediately following any confirmed or suspected ingestion exceeding the recommended therapeutic dosage. The official instruction requires immediate contact with emergency medical services or a certified Poison Control Center. Post-overdose management involves general supportive measures, maintaining a clear airway, and, in some cases, specific procedures like gastric decontamination. Monitoring requirements typically include continuous cardiac (ECG) observation and serial laboratory testing to assess organ function. These measures are defined to mitigate the risk of serious outcomes, especially in populations with pre-existing conditions like hepatic impairment.

Therapeutic Uses of Pyralgivet

What Pyralgivet treats: Main Uses and Benefits

Pyralgivet (Metamizole Sodium) is primarily used to provide symptomatic support within three primary therapeutic domains. It is applied when patients experience acute discomfort that requires symptomatic assistance.

The medicine helps address symptom clusters that may become intense or disruptive, and it is commonly used to help with: moderate to severe acute pain, especially postoperative and post-traumatic discomfort; painful smooth muscle spasms, such as those associated with renal or biliary colic; and symptoms related to systemic imbalance that may require additional management (referring to high fever).

The overall benefit is concentrated on immediate symptom relief. “It supports the patient during difficult episodes by easing distress and supports the patient during difficult episodes when symptoms are more noticeable.” This supportive assistance is relevant when acute manifestations interfere significantly with functional stability, assisting with maintaining comfort during periods of heightened symptoms.

Quick Fact: Relief for Acute Discomfort and Spasms

Pyralgivet is considered relevant in contexts marked by increased discomfort or tension, often used during phases when symptoms become temporarily overwhelming. It contributes to easing the overall symptom load when functional stability is affected by acute pain and spasms.

Eligibility and Restrictions for Use

Official Eligibility Profile

Pyralgivet (Metamizole Sodium) eligibility is strictly defined by regulatory documents, which establish clear restrictions based on patient history, age, and physiological status.

Contraindicated Populations (Must NOT Use)	Official Regulatory Status
History of hypersensitivity to metamizole, pyrazolones, or pyrazolidines	Absolute Contraindication
Impaired bone marrow function or diseases of the hematopoietic system	Absolute Contraindication
Third trimester of pregnancy	Absolute Contraindication
Infants below 3 months of age or mathbf5 kg body weight	Absolute Contraindication
Patients with acute intermittent hepatic porphyria or genetic G6PD deficiency	Absolute Contraindication

Age and Conditional Restrictions

The medicine is generally approved for adults and adolescents mathbfge 15 years of age (mathbfge 53 kg) and for children from mathbf3 months of age who require treatment. Use is not recommended for repeated administration during breastfeeding; if a single dose is used, the regulatory guidance states that breast milk must be discarded for a mathbf48-hour period.

Caution is required, and high doses are generally avoided, in the elderly and in patients with hepatic or renal impairment due to reduced drug elimination. The label also advises caution for patients with unstable circulation or pre-existing hypotension.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes specific circumstances and medicine types that require caution or avoidance when used concomitantly with Pyralgivet.

Pharmacokinetic and Pharmacodynamic Constraints

Pyralgivet is documented to have an enzyme induction effect, primarily as a moderate to strong inducer of the Cytochrome P450 enzymes CYP3A4, CYP2B6, and CYP2C19. This induction can lead to reduced plasma concentrations and potentially decreased efficacy of medicines that are substrates for these specific enzymes. Additionally, a pharmacodynamic interaction occurs with acetylsalicylic acid (ASA), where simultaneous intake of Pyralgivet may inhibit the antiplatelet effect of ASA.

Interaction-Related Restrictions

Co-administration is restricted for agents that share a risk of blood cell disorders. Pyralgivet is contraindicated in patients with a history of agranulocytosis caused by the medicine itself or other pyrazolones/pyrazolidines. Extreme caution is required when Pyralgivet is used alongside any medicine known to cause agranulocytosis. Furthermore, the use of antibiotics may mask the early symptoms of agranulocytosis, requiring heightened clinical awareness in such combinations. These restrictions establish the boundaries for safe co-prescription, focusing on mitigating hematological risk and maintaining the effectiveness of co-administered drugs.

Mechanism of Action

The pharmacological action of Pyralgivet stems from its active metabolite, 4-Methylaminoantipyrine (4-MAA), which influences three primary mechanistic domains.

Central Suppression of Nociceptive and Thermoregulatory Gateways

This mechanism primarily acts within the Central Nervous System (CNS), focusing on inhibiting the COX-3 enzyme and modulating the body's intrinsic opioidergic and cannabinoid systems. By reducing PGE 2 synthesis in the hypothalamus and influencing descending pain inhibition, the mechanism modulates the transmission of nociceptive signals and influences the elevated thermoregulatory set point.

Targeted Visceral Smooth Muscle Relaxation

The metabolite directly interferes with molecular mechanisms that regulate muscle contraction, specifically by inhibiting the mobilization and release of intracellular calcium ( Ca^2+) within smooth muscle cells. This action leads to a spasmolytic effect, reducing excessive contractile tension in non-vascular visceral organs, such as the urinary and gastrointestinal tracts.

Specificity and Limited Peripheral Action

The molecular profile of 4-MAA shows a preference for CNS targets like COX-3 over peripheral COX-1 and COX-2 enzymes. This mechanistic specificity means the mechanism focuses on modulating central pain and temperature pathways and, consequently, results in limited modulation of peripheral inflammatory PGE 2 synthesis.

Dosage and Administration Information

Administration Guidelines for Pyralgivet (Veterinary Use)

Pyralgivet, an injectable solution containing metamizole sodium, is intended for administration as outlined for veterinary use. The following details describe the standard administration procedure.

Administration Scope	Detail
Route of Administration	Intramuscular (IM) injection. In horses and cattle, slow intravenous (IV) administration is also an option.
Dosing Schedule	The dosage is calculated based on the animal’s body weight and target species. A common dose range for the active substance is 10 to 15 mg per 1 kg of body weight of the animal. Doses vary depending on whether the target is cattle, horses, pigs, or dogs.
Frequency Pattern	Typically administered as a single dose or repeated based on clinical need, rather than a fixed daily regimen. The dose may be repeated two to three times per day depending on the species and clinical requirement.

Procedural Requirements

The preparation and administration are performed by a veterinary professional or under their direct supervision. The injection solution is ready for use, requiring no prior dilution or reconstitution.

Preparation: The calculated volume of the solution is drawn aseptically into a sterile syringe.
Injection: The dose is administered via deep intramuscular injection. If the intravenous route is used in applicable species, the injection is given slowly to manage the risk of an anaphylactic reaction.
Missed Dose: Instructions for a missed dose are not applicable, as the drug is used for short-term symptomatic relief rather than chronic scheduling.

Proper administration of this injectable product relies on accurate weight-based dosing and the professional nature of the procedure.

Recent Clinical Evidence

Pyralgivet: Recent Clinical Evidence

Evidence for use in Acute Moderate to Severe Pain

Research primarily consists of Randomized Controlled Trials (RCTs) and systematic reviews that explored Pyralgivet in acute settings, such as post-operative discomfort. Studies monitored outcomes related to physical discomfort by tracking changes in pain intensity metrics and the time elapsed before participants used rescue medication. The primary focus of this evidence has been on short-term use, often less than two weeks, and data beyond the immediate acute phase are not fully established.

Evidence for use in Painful Smooth Muscle Spasms (Colic)

Research in conditions characterized by acute, episodic manifestations, like renal or biliary colic, largely comes from RCTs and reviews. Studies monitored pain score metrics and the necessity for subsequent medical intervention during the acute episode. The primary limitation here is that the evidence is generally focused on acute symptom change, and follow-up durations were limited.

Evidence for use in High Fever (Antipyresis)

Research explored Pyralgivet in the context of high fever using RCTs and reviews, examining temporary physiological imbalance by monitoring temperature change profiles. While robust evidence exists for febrile children, comparative data are generally less extensive for the adult population, meaning information for certain groups remains insufficient.

Evidence in Special Populations

Research has explored specific subgroups, such as febrile children, where substantial comparative evidence exists regarding temperature change outcomes. Conversely, studies that included older adults are less extensive, and dedicated large-scale studies focusing exclusively on this demographic are limited.

Long-term Studies and Follow-up Data

Research relevant to Pyralgivet largely focuses on trials assessing short-term or episodic symptom patterns, which forms a substantial part of the evidence landscape. The primary limitation across all indications is that follow-up durations were limited, and long-term data are not fully established.

What is Still Uncertain About Pyralgivet Research

Certainty remains low in several areas due to documented research limitations. Comparative evidence is lacking to thoroughly assess all doses and all routes of administration against all available comparator medicines. Additionally, evidence quality varies across studies, with some older research having limitations in study design.

Frequently Asked Questions (FAQ)

Common questions about Pyralgivet (FAQ)

Q: Does Pyralgivet have a high risk of side effects?

A: Official documentation describes the overall safety profile based on its specific mechanism of action. The most serious potential side effect, a severe reduction in white blood cells known as agranulocytosis, is described as very rare, with studies examining its occurrence rate.

Q: Are there any specific safety warnings associated with Pyralgivet use?

A: Yes, regulatory warnings advise careful use in patients with pre-existing heart or liver diseases, and avoidance if severe kidney problems are present. Furthermore, if the injection form is given intravenously, regulatory documents specify that it should be administered slowly due to the risk of a severe allergic response.

Q: How long does the effect of one dose of Pyralgivet usually last?

A: According to official product information, the pain-relieving effects usually begin within 30 minutes after administration. Pharmacological studies indicate that the effects of a single dose are described as persisting for approximately 4 hours.

Q: What happens if I accidentally take two doses of Pyralgivet close together?

A: Guidance for acute overdose or toxicity advises supportive measures. Regulatory guidance for this situation often involves measures to limit the body's absorption of the medicine, such as the use of activated charcoal.

Q: Does taking Pyralgivet with food make a difference?

A: For the oral forms of the medicine (tablets or solution), some administration guidelines state that it can be taken with food or immediately following a meal.

Q: What information is available regarding the use of Pyralgivet with alcohol?

A: Some official medicine instructions specifically state that the consumption of alcohol should be avoided while using this medicine.

Q: Is it true that official information suggests certain precautions when using Pyralgivet?

A: Yes, regulatory guidance advises supervision to monitor the medicine’s effects, especially in patients with pre-existing conditions like liver or kidney issues. It is important that the medicine not be used unsupervised for prolonged periods.

Q: Can Pyralgivet be taken with common vitamins or supplements?

A: The medicine is noted to have a low potential for interactions with most concurrently used medicines or supplements. However, caution is advised when Pyralgivet is combined with any agents known to potentially affect bone marrow function.

Q: Does Pyralgivet interact with hormonal birth control?

A: Official regulatory information specifies that use of this medicine may reduce the effectiveness of hormonal contraceptives.

Q: Does Pyralgivet affect lab test results?

A: The most significant potential side effect involves the blood-forming system (hematopoietic system), which requires monitoring via lab tests. Because of this connection, the active ingredients are known to be associated with blood disorders.

Q: How is Pyralgivet different from standard over-the-counter options?

A: Official sources classify the active ingredient as a non-opioid analgesic, antipyretic, and spasmolytic agent. Its mechanism is described as acting primarily on the central nervous system, a key difference from many common peripheral-acting options.

Q: Do people take Pyralgivet for short-term or long-term issues?

A: Regulatory-cited evidence indicates the medicine can be used in both short-term pain relief and certain long-term pain therapies. However, official warnings state that chronic, unsupervised use increases the probability of developing the severe adverse effect of agranulocytosis.

Q: Is it true that Pyralgivet can cause changes in sleep patterns?

A: Official documentation lists nervous system disorders like drowsiness and fatigue as potential side effects. These types of effects could potentially be linked to changes in sleep patterns.

Q: Is Pyralgivet available in different strengths?

A: Regulatory documents describe different dosing recommendations, including the use of high-dose therapy levels of the active substance. This indicates that specific milligram strengths are available for oral and injectable use.

Q: Does taking Pyralgivet mean I can't have caffeine?

A: Research has examined the effect of combining the active ingredient with caffeine. Studies indicate that this combination may change or potentiate (strengthen) the pain-relieving effect in some models.

Q: How quickly do most people notice the effects of Pyralgivet?

A: According to official product information, the pain-relieving effect of the active ingredients is documented to start within 30 minutes after administration.

Q: Can Pyralgivet be used by people with a history of heart issues?

A: Regulatory information advises that the use of the medicine should be strictly controlled for patients with pre-existing cardiac diseases. Furthermore, it is contraindicated for patients with conditions involving unstable circulation or pre-existing low blood pressure (hypotension).

Q: Why is Pyralgivet sometimes described as 'non-addictive'?

A: The medicine is formally classified by regulatory bodies as a non-opioid analgesic. While its mechanism influences the body's internal pain systems, official information indicates it does not produce the same level of physical dependence as conventional opioid medicines.

Q: What if I have an allergic reaction to Pyralgivet? What are the typical signs?

A: Official documentation lists signs of a possible allergic reaction, which may include rash, itching, difficulty breathing, or tightness in the chest. Swelling of the face, eyes, lips, tongue, or throat are also listed as signs.

Q: Can Pyralgivet cause drowsiness or affect driving?

A: Official documentation lists side effects such as drowsiness and fatigue that may be possible. Due to the potential for these effects, the ability to drive or operate heavy machinery may be impaired.

Q: Is it possible for Pyralgivet to stop working after a while?

A: Studies have examined that when administered repeatedly over time, tolerance to the antinociceptive (pain-blocking) effects may develop.

Q: How should I store Pyralgivet?

A: Regulatory-supported stability studies suggest that the injection solution should be stored at controlled temperatures, typically either ambient room temperature (around 22 C) or refrigerated (around 4 C), to help maintain the product's quality.

Q: Are there any specific warnings about taking Pyralgivet before surgery?

A: Regulatory guidance notes that this medicine is used in perioperative analgesia (pain relief around the time of surgery) in some regions. Practitioners are advised to monitor for adverse events in the surgical context.

Q: Is there a generic version of Pyralgivet available?

A: The active ingredient in Pyralgivet is Metamizole, which is also commonly known as Dipyrone. Official sources confirm that this substance is available globally under various generic and brand-name preparations.

Q: Are there any known long-term side effects associated with Pyralgivet?

A: While long-term pain relief may be possible, official documentation advises that chronic unsupervised use is associated with a risk of developing agranulocytosis and other hematologic disorders. These hematologic disorders are the primary long-term safety concerns described in regulatory literature.

Q: Is it considered normal to feel a mild headache after starting Pyralgivet?

A: Official documentation lists headaches among the documented disorders of the nervous system that are possible side effects of the medicine.

Q: Is there a list of foods or drinks to avoid while using Pyralgivet?

A: Official guidance specifically advises that the consumption of alcohol should be avoided while using this medicine. However, the oral forms of the medicine can generally be taken with or immediately after food.

Q: Is Pyralgivet commonly prescribed outside of the hospital setting?

A: The legal status of the active ingredient varies globally, ranging from prescription-only status to over-the-counter availability in different countries. This legal classification directly impacts whether it is typically used in a hospital or an outpatient setting.

How should Pyralgivet be stored and disposed of?

How to Store and Dispose of Pyralgivet: Official Regulatory Information

The official storage and disposal requirements for Pyralgivet, as documented by government regulatory agencies, define the conditions necessary to maintain the product's stability and ensure environmental safety.

Requirement	Official Regulatory Statement
Labeled storage temperature requirements	Specific temperature range not available from public government sources.
Light/moisture protection requirements	Specific environmental protection requirements not available from public government sources.
Stability after opening/reconstitution	In-use stability period not available from public government sources.
Child-protection storage requirements	Specific official instruction to keep out of children's reach not available from public government sources.
Disposal instructions	Disposal must follow local environmental and pharmaceutical waste regulations. Unused product must not be discarded with household trash or wastewater unless specifically instructed by the medicine's labeling.

Summary

Official regulatory documents establish mandatory storage constraints to preserve the medicine's quality, typically defining the acceptable temperature and necessary protection from light or moisture. The label also sets out the mandated procedure for disposal of expired or unused medicine, which generally prohibits flushing or mixing with household waste. These procedures are intended to safeguard the environment and prevent accidental exposure.

Pyralgivet